CD79A and plasma cell myeloma: Tumour biologic relevance of these findings was revealed by our in vivo studies: (1) decreased myeloma-specific IgA serum levels and (2) decreased myeloma bone disease indicated diminished tumour burden in the MOPC315.BM MM model.